ChemotherapyFDA-approvedFirst-line
Paclitaxel
How it works
Interferes with cell division, preventing cancer cells from growing and dividing.
Cancer types
Efficacy
Studies show that paclitaxel can improve survival rates and delay disease progression in ovarian cancer patients.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Oral Paclitaxel as First-Line Treatment for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| New Oral Paclitaxel Shows Similar Efficacy to IV Paclitaxel in Breast Cancer | Breast Cancer | phase-2 | The objective response rate was 25.0% with DHP107 and 28.6% with IV paclitaxel. | Source → |
| Study of Genetic Causes of Neuropathy in Breast Cancer Patients | Breast Cancer | preclinical | — | Source → |
| Testing a New Treatment for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| First-line Treatment Study for Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-3 | — | Source → |
| Testing IACS-6274 with or without Bevacizumab and Paclitaxel for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Testing CFI-402257 with Paclitaxel in Advanced Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Testing a Combination Treatment for Early-stage Triple-negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Paclitaxel Infusion Study | Breast Cancer | preclinical | — | Source → |
| Paclitaxel for Breast Cancer: A Bioequivalence Study | Breast Cancer | preclinical | — | Source → |
| Paclitaxel Linked to Rare Heart Condition in Breast Cancer Patient | Breast Cancer | observational | — | Source → |
| Link between erythropoietin receptor and ovarian cancer resistance found | Breast Cancer | lab-study | — | Source → |
| Delivering Cancer Medicine with Stem Cell Exosomes | Pancreatic Cancer | lab-study | PTX-loaded exosomes significantly enhanced cytotoxicity compared to free PTX, reducing IC values from 12.48 nM to 7.55 nM in BxPC-3 cells and from 22.44 nM to 19.29 nM in PANC-1 cells. | Source → |
| Vitamin B May Help Reduce Side Effects of Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | A significant reduction in CIPN grade over time was found, with fewer patients progressing to higher grades in the prophylactic versus non-prophylactic group. | Source → |
| ZNF184 Linked to Breast Cancer Resistance to Paclitaxel | Breast Cancer | lab-study | — | Source → |
| TMEPAI Protein Contributes to Paclitaxel Resistance in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| New Nanosystem Combines Two Cancer Treatments for Better Effect | Melanoma | lab-study | — | Source → |
| Paclitaxel treatment may enhance immune response in aggressive breast cancer | Breast Cancer | lab-study | — | Source → |
| Combining Camrelizumab with Gemcitabine and Paclitaxel in Pancreatic Cancer Patients | Pancreatic Cancer | phase-2 | The median overall survival was 14.0 months, and the median progression-free survival was 6.4 months. | Source → |
| Nanoformulated Phytochemicals Show Promise Against Pancreatic Cancer | Pancreatic Cancer | preclinical | — | Source → |
| Paclitaxel Resistance in Ovarian Cancer: A Potential Target for Treatment | Ovarian Cancer | lab-study | — | Source → |
| Comparing Two Cancer Treatments for Ovarian Cancer | Ovarian Cancer | observational | The frequency of peripheral neuropathy in the nab-paclitaxel cohort (14%) was half that of the paclitaxel cohort (28%). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer | Ovarian Cancer | phase-2 | A 1-month improvement in median progression-free survival and overall survival improvement was seen in the combination arm versus single-agent nab-paclitaxel. | Source → |
| Combining paclitaxel and anlotinib for ovarian cancer treatment | Ovarian Cancer | phase-2 | The investigator-evaluated objective response rate was 56.8% in the intention-to-treat population. | Source → |
| Paclitaxel-resistant cancer cells may rely on unstable microtubules | Breast Cancer | lab-study | — | Source → |
| Comparing Treatments for Early Recurring Pancreatic Cancer | Pancreatic Cancer | observational | The gemcitabine plus nab-paclitaxel group had a median overall survival of 14.5 months, compared to 11.1 months in the FOLFIRINOX group. | Source → |
| Paclitaxel Nanoemulsions Show Promise in Treating Breast Cancer | Breast Cancer | lab-study | The nanoemulsion amplified paclitaxel-mediated chromatin condensation and expression of proteins involved in apoptosis, with a 2.5-fold increase in PARP1 cleavage and a 1.7-fold downregulation of BCL2 expression. | Source → |
| Hydrogen Sulfide May Enhance Paclitaxel's Effectiveness Against Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Researchers Identify Potential Target for Paclitaxel-Resistant Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Ovarian Cancer Cells Show Resistance to Paclitaxel in Lab Experiments | Ovarian Cancer | lab-study | — | Source → |
| Combining Paclitaxel with Autophagy Inhibitor May Improve Breast Cancer Treatment | Breast Cancer | animal-study | — | Source → |
| Combining Radiation and Chemotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-1 | The median overall survival was 22.3 months. | Source → |
| Vitamin E Form δ-Tocotrienol May Enhance Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Understanding Paclitaxel's Effect on Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Gemcitabine and Nab-paclitaxel Combination Therapy Linked to Lung Disease in Pancreatic Cancer Patients | Pancreatic Cancer | meta-analysis | — | Source → |
| New Injectable Gel for Pancreatic Cancer Treatment | Pancreatic Cancer | lab-study | — | Source → |
| Tenacissoside G May Help Overcome Paclitaxel Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.